CollPlant Biotechnologies Ltd. (CLGN)
NASDAQ: CLGN · Real-Time Price · USD
2.010
-0.090 (-4.29%)
At close: Dec 5, 2025, 4:00 PM EST
2.050
+0.040 (1.99%)
After-hours: Dec 5, 2025, 5:55 PM EST
CollPlant Biotechnologies Revenue
CollPlant Biotechnologies had revenue of $77.00K in the quarter ending September 30, 2025, with 1,825.00% growth. This brings the company's revenue in the last twelve months to $2.48M, up 280.77% year-over-year. In the year 2024, CollPlant Biotechnologies had annual revenue of $515.00K, down -95.30%.
Revenue (ttm)
$2.48M
Revenue Growth
+280.77%
P/S Ratio
9.64
Revenue / Employee
$43,421
Employees
57
Market Cap
25.68M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 515.00K | -10.44M | -95.30% |
| Dec 31, 2023 | 10.96M | 10.66M | 3,565.22% |
| Dec 31, 2022 | 299.00K | -15.34M | -98.09% |
| Dec 31, 2021 | 15.64M | 9.50M | 154.86% |
| Dec 31, 2020 | 6.14M | 3.82M | 164.75% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
CLGN News
- 10 days ago - COLLPLANT BIOTECHNOLOGIES REPORTS 2025 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - PRNewsWire
- 18 days ago - COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2025 THIRD QUARTER FINANCIAL RESULTS - PRNewsWire
- 5 weeks ago - CollPlant Expands its rhCollagen Distribution Capabilities in the United States and Canada - PRNewsWire
- 6 weeks ago - CollPlant's rhCollagen-Based BioInk Demonstrates Strong Performance Compared to Matrigel® in Study Conducted by Technion - Israel Institute of Technology - PRNewsWire
- 7 weeks ago - First-in-Kind Fully Humanized 3D Bioprinted Human Skin Model Developed by Mayo Clinic Researchers using CollPlant's rhCollagen-Based BioInk - PRNewsWire
- 2 months ago - CollPlant Biotechnologies Announces Positive Results from non-clinical Studies of its Photocurable Regenerative Dermal and Soft Tissue Filler - PRNewsWire
- 2 months ago - CollPlant Expands the Distribution of its VergenixSTR Product in Europe - PRNewsWire
- 3 months ago - CollPlant to Present at the 2025 International Conference on Biofabrication - PRNewsWire